Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. (February 2021)

• Record Type: Journal Article
• Authors: Abbar, B.; De Castelbajac, V.; Gougis, P.; Assoun, S.; Pluvy, J.; Tesmoingt, C.; Théou-Anton, N.; Cazes, A.; Namour, C.; Khalil, A.; Gounant, V.; Besse, B.; Zalcman, G.; Brosseau, S.
• Is Part Of: Lung cancer. Volume 152(2021)
• Page Start: 109
• Page End: 118
• Publication Date: 2021-02
• Subjects: Non-small-cell lung cancer -- Hyperprogressive disease -- Immunotherapy -- Programmed cell death 1 receptor -- Programmed cell death 1 ligand 2 protein -- Cytotoxic T-lymphocyte-associated protein 4 antigen; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2020.12.026
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: ICI-induced HP remains controversial because of a lack of consensual definition. HP definitions are very heterogeneous in terms of incidence rate and clinical impact. Agreement between HP definitions is heterogenous and globally poor. The presence of liver metastasis is associated with HP. Abstract: Background: The advent of immune checkpoint inhibitors (ICI) has been a breakthrough in the care of patients with non-small-cell lung cancers (NSCLC). However, physicians are now facing a previously unidentified clinical situation called hyperprogression (HP), which presents as a fast and unexpected increase in tumor burden. HP's existence and specificity to ICIs remains controversial because a widely acknowledged definition is currently lacking. Meanwhile, management remains elusive. Methods: Medical records from all consecutive NSCLC patients who were treated with ICI from 2015 to 2018 were retrospectively analyzed. The HP incidence rate was calculated according to five definitions (tumor growth rate [TGR]ratio, ΔTGR, tumor growth kinetic [TGK], RECIST, and time to treatment failure [TTF]), and the agreement between such definitions was determined. The HP impact on overall survival (OS) was then assessed. The association between HP (defined using the TGRratio definition) and clinical and biological variables was also assessed. Clinical HP management and its impact on outcomes were described. Results: We identified 169 consecutive ICI-treated patients, with potential HP accounting for 11.3 %, 5.7 %, 17.0 %, 9.6 %, and 31.7 % patients, according to TGRratio, ΔTGR, TGK, RECIST, and TTF definitions. Agreement between the different HP definitions was highly heterogeneous (range 29 %–77 %) and globally poor. HP was associated with shorter OS, compared to standard RECIST progressive disease, but this difference only reached statistical significance when using the TTF definition. TGRratio-based HP was significantly associated with hepatic metastases. In TGRratio-based HP patients, neither resuming chemotherapy nor corticosteroids use was associated with statistically significant impact on overall survival. Conclusion: We found fairly heterogeneous HP rates using different definitions. TTF was the only definition leading to significantly worsened OS. Further studies are needed to provide consensus recommendations for the assessment, definition, and management of HP, whose existence is likely real.